Many MIT CCR members are using vertebrate model organisms to study the role of known or putative cancer genes in both normal development and tumorigenicity. This includes a variety of mutant mouse strains that carry gain-of-function, loss-offunction and/or conditional alleles as well as a large collection of zebrafish strains that carry inactivating viral insertions within numerous genes essential for embryonic development. To support these studies, it is essential that researchers can correctly diagnose the resulting phenotypes and also recover tissue samples to investigate the underlying molecular changes. The Histology Core Facility?s mission is to provide CCR researchers with state-of-the-art histological services. The facility carries out the processing and sectioning of tissue samples and the generation of slides on a fee-for-service basis. It also provides cutting-edge intellectual and technical expertise. This includes advice on the generation and fixation of tissue samples and the availability and use of various staining procedures. In addition, a veterinary pathologist, Dr. Roderick Bronson, works in the Facility one day a week. Dr. Bronson is an internationally recognized expert in mouse pathology, and he is available to meet with CCR researchers to assist in the analysis of slides and the diagnosis of developmental and tumor phenotypes. This provides expert training of CCR students, postdocs and staff in histology and has played a significant role in promoting collaborative interactions, both between CCR investigator laboratories and with the wider cancer community, through the identification of shared or related phenotypes in different model systems. The centralization of histological analysis allows the MIT CCR to provide its investigators with a comprehensive range of services while minimizing staff and equipment costs and space requirements. Price comparisons show that the cost to CCR Investigators is highly competitive with those of other academic histology facilities within the Boston/Cambridge area and significantly cheaper than commercial options.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014051-37
Application #
7668631
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
37
Fiscal Year
2008
Total Cost
$395,030
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Lannagan, Tamsin R M; Lee, Young K; Wang, Tongtong et al. (2018) Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut :
Suzuki, Hiroshi I; Spengler, Ryan M; Grigelioniene, Giedre et al. (2018) Deconvolution of seed and RNA-binding protein crosstalk in RNAi-based functional genomics. Nat Genet 50:657-661
Roper, Jatin; Tammela, Tuomas; Akkad, Adam et al. (2018) Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. Nat Protoc 13:217-234
Richardson, Christopher E R; Cunden, Lisa S; Butty, Vincent L et al. (2018) A Method for Selective Depletion of Zn(II) Ions from Complex Biological Media and Evaluation of Cellular Consequences of Zn(II) Deficiency. J Am Chem Soc 140:2413-2416
McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge et al. (2018) JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest 128:789-804
Chen, Pan-Yu; Muzumdar, Mandar Deepak; Dorans, Kimberly Judith et al. (2018) Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 78:985-1002
Choudhury, Atish D; Werner, Lillian; Francini, Edoardo et al. (2018) Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3:
Viswanathan, Srinivas R; Nogueira, Marina F; Buss, Colin G et al. (2018) Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet 50:937-943
Wong, Madeline Y; Chen, Kenny; Antonopoulos, Aristotelis et al. (2018) XBP1s activation can globally remodel N-glycan structure distribution patterns. Proc Natl Acad Sci U S A 115:E10089-E10098

Showing the most recent 10 out of 904 publications